Definium Therapeutics Closes Underwriting Agreement for Public Offering
Definium Therapeutics agreed to sell 20.588 million common shares through an underwriting agreement led by J.P. Morgan. This transaction formalizes a capital raise to support biopharmaceutical operations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day